Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Acasti Pharma (ACST)

Acasti Pharma (ACST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. GlobeNewswire - Fri Oct 25, 2024

ACST : 3.37 (-0.88%)
Home Sales, U.S. CPI Lead Statistics List Baystreet - Fri Jun 21, 2024

MondayU.S. Featured Earnings Enerpac Tool Group Corp (NYSE: EPAC (Q3) EPS of 47 cents, compared ...

MKC : 54.33 (+1.99%)
DDD : 2.24 (+4.67%)
AGF-B.TO : 15.61 (+1.17%)
MU : 455.07 (-0.47%)
BB.TO : 6.63 (+3.27%)
NKE : 46.03 (+0.72%)
JEF : 48.09 (+3.29%)
PRGS : 30.93 (+3.72%)
GIS : 35.50 (+0.51%)
PAYX : 91.96 (-0.18%)
WBA : 11.98 (+0.50%)
XAIR : 0.5440 (+22.19%)
Acasti Pharma Announces 1-for-6 Reverse Stock Split PR Newswire - Fri Jul 7, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of...

ACST : 3.37 (-0.88%)
Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023 PR Newswire - Wed Jul 5, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel injectable...

ACST : 3.37 (-0.88%)
Acasti Pharma Reports Fiscal Year 2023 Operational Results PR Newswire - Fri Jun 23, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of...

ACST : 3.37 (-0.88%)
Short Week in U.S. Baystreet - Fri Jun 16, 2023

Monday U.S.Markets are closed for “Juneteenth” holiday.Canada Economic Lookahead ...

SCS : 16.14 (+0.12%)
BIGG.CN : 0.1450 (+3.57%)
ACN : 197.65 (+1.88%)
KBH : 54.28 (+4.53%)
FDS : 232.73 (+0.38%)
LZB : 35.87 (+5.16%)
KMX : 40.88 (+0.96%)
DRI : 201.07 (+2.24%)
ASE.CN : 2.4100 (+9.55%)
FDX : 392.38 (+3.02%)
ACST : 3.37 (-0.88%)
WGO : 33.74 (+4.14%)
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025 PR Newswire - Mon May 8, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of...

ACST : 3.37 (-0.88%)
Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND PR Newswire - Tue Apr 4, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, specialty pharma company advancing drug candidates for rare and...

ACST : 3.37 (-0.88%)
Acasti Pharma Inc. Announces the Resignation of a Director PR Newswire - Thu Mar 30, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST) a late-stage, specialty pharma company advancing three clinical stage drug...

ACST : 3.37 (-0.88%)
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange PR Newswire - Mon Mar 13, 2023

/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST) a late-stage, specialty pharma company advancing three clinical...

ACST : 3.37 (-0.88%)

Barchart Exclusives

Applebee’s and IHOP Owner Dine Brands Looks Ripe For A Buyout Barchart - Sun Apr 19, 2:18PM CDT
Dine Brands has already rallied on activist pressure, but with Applebee’s and IHOP still trading below their strategic value, private equity could be the next catalyst. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.